Ferritin Testing Market Analysis

Indication (Anemia, Hemochromatosis, Pregnancy, Lead Poisoning)

The anemia segment in the ferritin testing market is anticipated to hold the largest share of 35% by the end of 2036. A person with anemia does not have enough healthy red blood cells to properly oxygenate the body's tissues, which can lead to adverse effects on the body, such as fatigue, weakness, and headaches. Anemia can take many forms and each has its etiology. It can range from moderate to severe, and it can be temporary or permanent. According to the Global Nutrition Report, as of May 2021, 613.2 million adolescent girls and women aged 15 to 49 (32.8% prevalence) are affected by anemia, Prevalence in pregnant women (35.3 million, 40.1%) and non-pregnant women (577.9% prevalence). 1 million, 32.5%) adolescent girls and women. 

End Users (Hospitals, Diagnostic Laboratories, Specialty Clinics)

The hospital's segment is anticipated to account for the largest share of 45% by the end of 2036. The growing number of hospitals and their infrastructure development is expected to drive segment growth. According to the American Hospital Association survey, there are currently approximately 6,146 hospitals in the United States. The US spent about $3.6 trillion on health care in 2018, according to the Centers for Medicare and Medicaid Services.  During the projected time frame, rising hospital admission rates and the prevalence of iron deficiency are anticipated to fuel the expansion of the hospital sector in the worldwide ferritin testing market.

Our in-depth analysis of the global market includes the following segments: